BEST, Netherlands & TORONTO -- (Business Wire)
Royal Philips (NYSE: PHG, AEX : PHIA) and Profound Medical Corp. (TSXV:
PRN), a Toronto-based medical device company, today announced that they
have signed a joint development agreement to support Profound Medical’s
proprietary TULSA (Transurethral Ultrasound Ablation) technology
designed to treat patients with prostate cancer on Philips’ Ingenia and
Achieva 3T MRI systems.
Profound’s TULSA technology is emerging as a new minimally invasive,
whole gland ablation of the prostate. This single session procedure has
the potential for outcomes comparable to the best of current treatment
options, but with lower rates of side effects and higher quality of life
for patients.
“Philips has stepped forward and enthusiastically shares our vision for
the technology. With their support, TULSA-PRO will soon be available to
clinicians and patients for primary treatment of localized prostate
cancer,” says Steve Plymale, CEO, Profound Medical Corp. “This new
relationship will provide us with access to a large installed base of
MRI systems and customers and we look forward to developing this
mutually rewarding relationship further.”
As a leader in image-guided therapies Philips is expanding its efforts
in the fast growing interventional oncology domain. MRI is emerging in
oncology applications, because of its excellent real-time 3D
visualization of soft tissue and Philips has a suite of industry-leading
solutions for MRI guided procedures. Philips has deep expertise and
experience in providing clinical solutions for prostate MR imaging.
“With 3T MRI emerging as a technology standard for multi-parametric MRI
diagnostic imaging of the prostate, our collaboration with Profound
Medical will enable us to offer our customers access to a novel MR
guided ultrasound ablation therapy that’s critical to prostate care
research,” said Christopher Busch, General Manager MR Therapy, Philips
Medical Systems. “We look forward to teaming with Profound Medical to
refine the integration of our technologies and drive clinical research
and reimbursement efforts with the ultimate objective to improve
clinical performance and enhance the patient experience.”
Profound Medical will soon release 12 month data from its 30 patient
safety and feasibility study with the goal of obtaining a CE mark and
commercialization of TULSA-PRO in Europe and Canada in 2016.
About Profound Medical Corp.
Profound Medical is a Canadian medical device company that has developed
a unique and minimally invasive treatment to ablate the prostate gland.
Profound’s novel technology combines MRI technology with ultrasound
thermal energy that is delivered via a transurethral approach. This
method of prostate cancer therapy provides highly accurate and precise
treatment within the prostate in a short time span, allowing for fast
patient recovery. The potential of this technology is currently being
demonstrated in clinical trials. For more information, visit profoundmedical.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people's lives through
meaningful innovation in the areas of Healthcare, Consumer Lifestyle and
Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of
EUR 21.4 billion and employs approximately 108,000 employees with sales
and services in more than 100 countries. The company is a leader in
cardiac care, acute care and home healthcare, energy efficient lighting
solutions and new lighting applications, as well as male shaving and
grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721005283/en/
Contacts:
For Profound Medical investor or media inquiries, please contact:
Profound
Medical Corp.
Shameze Rampertab, 647-476-1350, Ext. 424
CFO
srampertab@profoundmedical.com
or
Rebecca
von Goetz, 647-476-1350, Ext. 426
Senior Marketing & Communications
Specialist
C: 417-917-8650
rvongoetz@profoundmedical.com
or
For
Philips media inquiries:
Royal Philips
Steve Klink,
31610888824
Press Officer
steve.klink@philips.com
Source: Royal Philips
© 2024 Canjex Publishing Ltd. All rights reserved.